Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 mRNA vaccineindustry 360º synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 End-use trends
Chapter 3 mRNA Vaccine Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of chronic and infectious disease
3.2.1.2 Increasing focus on preventive healthcare
3.2.1.3 Growing R&D investments for developing mRNA based vaccines
3.2.1.4 Increasing government initiatives and policies to promote vaccination
3.2.2 Industry pitfalls & challenges
3.2.2.1 High price associated with mRNA-based vaccines
3.2.2.2 Stringent regulations for the approval of mRNA vaccine
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.6 Future potential
3.7 Pipeline analysis
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Strategy outlook matrix
Chapter 5 mRNA Vaccine Market Size and Forecast, By Type (USD Million)
5.1 Key trends, by type
5.2 Self-amplifying mRNA vaccines
5.3 Conventional non-amplifying mRNA vaccines
Chapter 6 mRNA vaccine Market Size and Forecast, By End-use (USD Million)
6.1 Key trends, by end-use
6.2 Hospitals & clinics
6.3 Research laboratories
6.4 Other end-uses
Chapter 7 mRNA vaccine Market Size and Forecast, By Region (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 MEA
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 Rest of MEA
Chapter 8 Company Profiles
8.1 Pfizer Inc.
8.2 Moderna, Inc.
8.3 BioNTech SE
8.4 GlaxoSmithKline
8.5 Daiichi Sankyo
8.6 Ethris GmbH
8.7 AIM Vaccine
8.8 Arcturus Therapeutics Inc.
8.9 CureVac
8.10 AstraZeneca
8.11 Sanofi
